Precision Medicine Market:  Industry Size, Segments Overview, Business outlook, Trends, Global Forecast 2025

Adroit Market Research today published a study on the “Global Precision Medicine Market Size 2017 by Application (Oncology, Central Nervous System, Cardiology, Infectious disease and Others), Region and Forecast 2018 to 2025”. The global Precision Medicine market size is estimated based on the population genetic screening data, disease prevalence rate and adoption of the precision medicines across the globe. Global Precision Medicine manufacturers have varying products, depending on consumer genetic screening data.

Get more Information about this Report @ https://www.adroitmarketresearch.com/industry-reports/precision-medicine-market

The report also provides various key strategies adopted by the leading players as they mainly target prevalent diseases in the developed and developing economies. Precision Medicine market share in various diseases has also been derived on the basis of thorough understanding of the forecast and dynamics of various products under pipeline in various geographies. Also, the global Precision Medicine market size has been laid down based on an extensive value chain analysis and patent analysis.

The global precision medicine market size is projected to be valued USD 119.90 billion by 2025. Advancement in genomic and proteomic sequencing with reduced costs, is bringing in the so-called “genomic revolution.” By identifying the optimal point of intervention for treatment, healthcare providers massively improve the quality of care. Additionally, these technologies offer optimized cost by effectively timing treatment intervention and eliminating the need for insufficient or excessive treatment regimens.

Request Sample Pages for more Insights @ https://www.adroitmarketresearch.com/contacts/request-sample/831

Next generation sequencing has shifted the paradigm of genomics by accomplishing entire genome sequencing in a matter of hours. The enhanced speed and ease of DNA sequencing has drastically reduced the cost. The cost of deciphering the entire human genome has dropped by an order of magnitude from USD 10,000 in 2011 to about USD 1,000 today. As genome sequencing costs are declining rapidly healthcare providers and patients are likely to be more inclined to seek treatments that are targeted to a particular illness.

Cost is a major issue for precision medicines. Precision medicines may overburden many healthcare systems which are currently under significant financial constraints. It is a major factor hindering the patient’s access to treatment. The new targeted drugs that are launched in the market are so highly priced that the patients can hardly afford them unless the cost is fully covered by the payers.

For Any Query on the Precision Medicine Market @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/831

Key segments of the global precision medicine market
Application Overview, 2015-2025 (USD Million)
• Oncology
• CNS
• Cardiology
• Infectious disease
• Others

Some of the leading players operating in the market include Novartis International AG, F. Hoffmann-La Roche AG, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Merck & Co. and others.

About us:
We are here to provide credible market intelligence with actionable insights. We believe that with the fast changing business environment and rapid turns in economic cycles, a lot is overlooked. With the aid of technology, a large amount of data is produced which is waiting to be analyzed and patterned. The insights which can be mined from such a large amount of data can enable businesses to grow at a pace of their choosing, be it long term goals or short-term goals. Being aware of the market movements allows for agility and agility is one of the highest rated characteristics of modern businesses.

Contact us:
Contact Name: Ryan Johnson
Contact Email: sales@adroitmarketresearch.com
Contact Phone: +1 (214) 884-6068

This release was published on openPR.